GT Biopharma (GTBP) Income from Continuing Operations (2010 - 2026)

GT Biopharma (GTBP) has reported Income from Continuing Operations for 17 consecutive years, with -$2.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 49.68% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$13.2 million, a 2.56% decrease from a year earlier, with the FY2025 full-year figure at -$12.4 million, up 11.0% from the prior year.
• Income from Continuing Operations was -$2.8 million for Q1 2026 at GT Biopharma, up from -$5.6 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at -$1.5 million in Q2 2025 and troughed at -$7.0 million in Q3 2022.
• A 5-year average of -$3.7 million and a median of -$3.5 million in 2024 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations surged 81.68% in 2022 and plunged 50.59% in 2025, its largest moves.
• Over 5 years, Income from Continuing Operations stood at -$5.8 million in 2022, then soared by 48.98% to -$2.9 million in 2023, then slipped by 25.64% to -$3.7 million in 2024, then sank by 50.59% to -$5.6 million in 2025, then surged by 49.01% to -$2.8 million in 2026.
• The last three Income from Continuing Operations figures came in at -$2.8 million (Q1 2026), -$5.6 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.